JP5656883B2 - エスゾピクロンを用いる治療方法 - Google Patents
エスゾピクロンを用いる治療方法 Download PDFInfo
- Publication number
- JP5656883B2 JP5656883B2 JP2012004970A JP2012004970A JP5656883B2 JP 5656883 B2 JP5656883 B2 JP 5656883B2 JP 2012004970 A JP2012004970 A JP 2012004970A JP 2012004970 A JP2012004970 A JP 2012004970A JP 5656883 B2 JP5656883 B2 JP 5656883B2
- Authority
- JP
- Japan
- Prior art keywords
- eszopiclone
- aphasia
- pain
- zopiclone
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Description
活性成分エスゾピクロン、ラクトース、及びコーンスターチを均一になるまでブレンドし;次に、得られた粉末中にステアリン酸マグネシウムをブレンドする。得られた混合物を適当な大きさのツーピース硬質ゼラチンカプセル中にカプセル充填する。
活性成分エスゾピクロンを適当な篩を通して篩にかけ、そして、ラクトース、スターチ、及びアルファ化コーンスターチとブレンドする。適当な容量の精製水を添加し、粉末を顆粒化する。乾燥後、顆粒を篩にかけ、ステアリン酸マグネシウムとブレンドする。次に、7mm直径の穿孔機を使用して、顆粒を圧縮し、錠剤とする。
本研究は、リウマチ様関節炎に関連する不眠症を有する対象における昼間機能に対するエスゾピクロン3mgの効果をプラセボと比較して観察することを目的とした。試験は、多施設、ランダム化、二重盲検、プラセボ対照、平行群間試験であった。試験は、1週間の単純盲検プラセボ導入期間、その後4週間の二重盲検治療、そして1週間の単純盲検プラセボウォッシュアウトを行なった。
本研究は、更年期又は閉経に対する二次的な不眠症の治療におけるエスゾピクロン3mgの効果を、プラセボと比較して観察することを目的とした。試験は、多施設、ランダム化、二重盲検、プラセボ対照、平行群間試験であった。試験は、1週間の単純盲検プラセボ導入期間、その後4週間の二重盲検治療、そして1週間の単純盲検プラセボウォッシュアウトを行なった。主要な解析法は、二つの治療群間のランダム化後の結果を比較した。
Claims (4)
- エスゾピクロンを有効成分として含む、痛みに関連する疲労(但し、筋肉の痙攣由来の痛みに関連する疲労を除く)の治療用医薬。
- 非経口的に、経皮的に、経口的に又は吸入により投与するための、請求項1に記載の医薬。
- 前記有効成分を1日当たり0.5mg〜15mgの量で投与する、請求項1又は2に記載の医薬。
- 前記有効成分を1投薬当たり0.5mg、1.0mg、2.0mg及び3.0mgから選択される量で投与する、請求項3に記載の医薬。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55959004P | 2004-04-05 | 2004-04-05 | |
US60/559,590 | 2004-04-05 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007506373A Division JP4970244B2 (ja) | 2004-04-05 | 2005-04-05 | エスゾピクロンを用いる治療方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012102137A JP2012102137A (ja) | 2012-05-31 |
JP5656883B2 true JP5656883B2 (ja) | 2015-01-21 |
Family
ID=34967775
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007506373A Expired - Fee Related JP4970244B2 (ja) | 2004-04-05 | 2005-04-05 | エスゾピクロンを用いる治療方法 |
JP2012004970A Active JP5656883B2 (ja) | 2004-04-05 | 2012-01-13 | エスゾピクロンを用いる治療方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007506373A Expired - Fee Related JP4970244B2 (ja) | 2004-04-05 | 2005-04-05 | エスゾピクロンを用いる治療方法 |
Country Status (6)
Country | Link |
---|---|
US (3) | US7776858B2 (ja) |
EP (1) | EP1732559B1 (ja) |
JP (2) | JP4970244B2 (ja) |
AU (1) | AU2005231490B2 (ja) |
CA (3) | CA2677470A1 (ja) |
WO (1) | WO2005097132A2 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1691811E (pt) * | 2003-12-11 | 2014-10-30 | Sunovion Pharmaceuticals Inc | Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão |
ATE454140T1 (de) | 2004-02-18 | 2010-01-15 | Sepracor Inc | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität |
US7776858B2 (en) * | 2004-04-05 | 2010-08-17 | Sepracor Inc. | Methods of treatment of chronic pain using eszopiclone |
US20080293726A1 (en) | 2005-07-06 | 2008-11-27 | Sepracor Inc. | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders |
CA2637542A1 (en) | 2006-01-17 | 2007-07-26 | Glenmark Pharmaceuticals Limited | Improved process for the preparation of an optically active 5h-pyrrolo [3,4-b] pyrazine derivative |
EP2020403A1 (en) | 2007-08-02 | 2009-02-04 | Esteve Quimica, S.A. | Process for the resolution of zopiclone and intermediate compounds |
CA2703138A1 (en) * | 2007-10-26 | 2009-04-30 | F. Hoffmann-La Roche Ag | Purine derivatives useful as pi3 kinase inhibitors |
US8269005B2 (en) * | 2007-12-19 | 2012-09-18 | Sunovion Pharmaceuticals Inc. | L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine |
US20110053945A1 (en) * | 2007-12-19 | 2011-03-03 | Sepracor Inc. | Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihy-dro-5h-pyrrolo[3,4-b]pyrazine |
US8268832B2 (en) | 2007-12-19 | 2012-09-18 | Sunovion Pharmaceuticals Inc. | Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine |
US8198277B2 (en) | 2007-12-19 | 2012-06-12 | Sunovion Pharmaceuticals Inc. | L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine |
WO2009085972A1 (en) * | 2007-12-19 | 2009-07-09 | Sepracor Inc. | Maleate, besylate, and l-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine |
US8198278B2 (en) | 2007-12-19 | 2012-06-12 | Sunovion Pharmaceuticals Inc. | Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine |
US8212036B2 (en) | 2007-12-19 | 2012-07-03 | Sunovion Pharmaceuticals Inc. | Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine |
US20090269409A1 (en) * | 2008-04-24 | 2009-10-29 | Mukesh Kumar Garg | Pharmaceutical compositions comprising eszopiclone |
CA2750059C (en) | 2009-01-30 | 2014-11-18 | Sunovion Pharmaceuticals Inc. | Coated tablets of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine and methods for measuring effectiveness of coating |
US20110009416A1 (en) * | 2009-07-07 | 2011-01-13 | Sepracor Inc. | PH INDEPENDENT FORMULATIONS OF 6-(5-CHLORO-2-PYRIDYL)-5-[(4-METHYL-1-PIPERAZINYL)CARBONYLOXY]-7-OXO-6,7-DIHYDRO-5H-PYRROLO[3,4-b]PYRAZINE |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2671800B1 (fr) * | 1991-01-17 | 1993-03-12 | Rhone Poulenc Rorer Sa | Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent. |
US5786357A (en) * | 1991-12-02 | 1998-07-28 | Sepracor Inc. | Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone |
AU3245593A (en) * | 1991-12-02 | 1993-06-28 | Sepracor, Inc. | Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone |
WO1993010788A1 (en) * | 1991-12-02 | 1993-06-10 | Sepracor, Inc. | Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone |
US6339086B1 (en) * | 1999-05-14 | 2002-01-15 | Swpracor, Inc. | Methods of making and using N-desmethylzopiclone |
WO2004037212A2 (en) * | 2002-10-24 | 2004-05-06 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
PT1691811E (pt) * | 2003-12-11 | 2014-10-30 | Sunovion Pharmaceuticals Inc | Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão |
WO2005063248A1 (en) | 2003-12-22 | 2005-07-14 | Sepracor Inc. | Modafinil combination therapy for improving sleep quality |
US20050164987A1 (en) * | 2003-12-24 | 2005-07-28 | Barberich Timothy J. | Melatonin combination therapy for improving sleep quality |
ATE454140T1 (de) * | 2004-02-18 | 2010-01-15 | Sepracor Inc | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität |
US7465729B2 (en) * | 2004-04-05 | 2008-12-16 | Sepracor Inc. | Methods of treatment of menopause and perimenopause using eszopiclone |
US7776858B2 (en) * | 2004-04-05 | 2010-08-17 | Sepracor Inc. | Methods of treatment of chronic pain using eszopiclone |
CA2670593A1 (en) | 2006-12-01 | 2008-06-12 | Sepracor Inc. | Treatment of anxiety with eszopiclone |
-
2005
- 2005-04-05 US US11/099,078 patent/US7776858B2/en active Active
- 2005-04-05 CA CA002677470A patent/CA2677470A1/en not_active Abandoned
- 2005-04-05 WO PCT/US2005/011593 patent/WO2005097132A2/en not_active Application Discontinuation
- 2005-04-05 CA CA002677465A patent/CA2677465A1/en not_active Abandoned
- 2005-04-05 JP JP2007506373A patent/JP4970244B2/ja not_active Expired - Fee Related
- 2005-04-05 AU AU2005231490A patent/AU2005231490B2/en not_active Ceased
- 2005-04-05 EP EP05734186.9A patent/EP1732559B1/en not_active Not-in-force
- 2005-04-05 CA CA002557850A patent/CA2557850A1/en not_active Abandoned
-
2010
- 2010-07-19 US US12/838,554 patent/US8071599B2/en not_active Expired - Fee Related
-
2011
- 2011-10-12 US US13/271,825 patent/US8247417B2/en active Active
-
2012
- 2012-01-13 JP JP2012004970A patent/JP5656883B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CA2677470A1 (en) | 2005-10-20 |
JP4970244B2 (ja) | 2012-07-04 |
JP2007531745A (ja) | 2007-11-08 |
JP2012102137A (ja) | 2012-05-31 |
EP1732559A2 (en) | 2006-12-20 |
US20050222156A1 (en) | 2005-10-06 |
US20100280038A1 (en) | 2010-11-04 |
US20120035182A1 (en) | 2012-02-09 |
US7776858B2 (en) | 2010-08-17 |
AU2005231490B2 (en) | 2011-05-19 |
CA2677465A1 (en) | 2005-10-20 |
WO2005097132A3 (en) | 2006-02-16 |
AU2005231490A1 (en) | 2005-10-20 |
WO2005097132A2 (en) | 2005-10-20 |
CA2557850A1 (en) | 2005-10-20 |
EP1732559B1 (en) | 2017-03-22 |
US8071599B2 (en) | 2011-12-06 |
US8247417B2 (en) | 2012-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5656883B2 (ja) | エスゾピクロンを用いる治療方法 | |
US6342496B1 (en) | Bupropion metabolites and methods of use | |
US7465729B2 (en) | Methods of treatment of menopause and perimenopause using eszopiclone | |
US20060025418A1 (en) | Methods of making and using N-desmethylzopiclone | |
AU2008283989B2 (en) | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands. | |
MX2008000249A (es) | Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos. | |
JPH07501547A (ja) | 光学的に純粋な(−)アムロジピンを用いる,高血圧,狭心症および他の疾患を治療するための方法および組成物 | |
MX2008007589A (es) | Un metodo para tratar eyaculacion prematura en seres humanos. | |
US20140271890A1 (en) | Controlled-release pharmaceutical composition | |
US20120046302A1 (en) | Methods of treating cns disorders | |
JP2005194263A (ja) | D4および5−ht2aアンタゴニスト、逆アゴニストまたは部分アゴニストの使用 | |
WO2010126527A1 (en) | Methods of treating cns disorders | |
CA2654557A1 (en) | Combination preparations comprising bifeprunox and l-dopa | |
Rivera-García et al. | The Resurgence of Hallucinogen Drugs in Clinical Research | |
US7915262B2 (en) | Combination preparations comprising SLV308 and a dopamine agonist | |
AU2011202540B2 (en) | Methods of treatment using eszopiclone | |
JP2004505919A (ja) | 一次性頭痛の処置におけるビタミン配合物の使用 | |
US8106056B2 (en) | Combination preparations comprising bifeprunox and a dopamine agonist | |
JP2002255820A (ja) | モノアミン作動性神経の活性化剤 | |
JP2010222347A (ja) | Pde5阻害剤及びカルニチンを含有する医薬組成物 | |
ZA200109383B (en) | Methods of making and using N-desmethylzopiclone. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130917 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131217 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140117 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140217 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140317 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140617 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141014 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141021 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141111 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141125 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5656883 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |